Biomea Fusion Files 8-K: Regulation FD & Other Events

Ticker: BMEA · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1840439

Biomea Fusion, Inc. 8-K Filing Summary
FieldDetail
CompanyBiomea Fusion, Inc. (BMEA)
Form Type8-K
Filed DateDec 20, 2024
Risk Levellow
Pages5
Reading Time7 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, regulation-fd

TL;DR

Biomea Fusion dropped an 8-K on 12/17 covering Reg FD and other events. Check it out.

AI Summary

On December 17, 2024, Biomea Fusion, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, with financial statements and exhibits also included. The company is incorporated in Delaware and its principal executive offices are located at 900 Middlefield Road, 4th Floor, Redwood City, California.

Why It Matters

This 8-K filing provides important updates and disclosures from Biomea Fusion, Inc. to the public, ensuring transparency regarding company events and regulatory compliance.

Risk Assessment

Risk Level: low — This filing is a standard 8-K report detailing corporate events and disclosures, not indicating any immediate financial distress or significant operational change.

Key Numbers

  • 001-40335 — SEC File Number (Identifies the company's filing with the SEC.)
  • 1231 — Fiscal Year End (Indicates the end of the company's fiscal year.)

Key Players & Entities

  • Biomea Fusion, Inc. (company) — Registrant
  • Delaware (jurisdiction) — State of incorporation
  • 900 Middlefield Road, 4th Floor, Redwood City, California 94063 (location) — Principal executive offices address
  • December 17, 2024 (date) — Date of earliest event reported

FAQ

What specific events are being disclosed under Regulation FD?

The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the provided text snippet.

What are the 'Other Events' mentioned in the filing?

The filing lists 'Other Events' as an item, but the specific nature of these events is not detailed in the provided text.

What is the significance of the 'Financial Statements and Exhibits' being included?

This suggests that the filing may contain or refer to financial information and supporting documents relevant to the reported events.

When was the report filed with the SEC?

The report was filed as of date December 20, 2024.

What is Biomea Fusion, Inc.'s primary industry?

Biomea Fusion, Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.

Filing Stats: 1,638 words · 7 min read · ~5 pages · Grade level 13.8 · Accepted 2024-12-20 15:06:04

Key Financial Figures

  • $0.0001 — ange on which registered Common Stock, $0.0001 par value BMEA The NASDAQ Global Se

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press release titled "Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes," issued by Biomea Fusion, Inc. on December 17, 2024, furnished herewith. 99.2 Corporate presentation titled "Covalent-111 Topline Results" dated December 17, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Biomea Fusion Inc. Date: December 20, 2024 By: /s/ Thomas Butler Thomas Butler Principal Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.